Gliquidonum
Glurenorm is a medicine that lowers blood sugar levels, belonging to the group of sulfonylurea derivatives.
Glurenorm is indicated for the treatment of type 2 diabetes in adult patients, in whom dietary measures alone are not sufficient to control carbohydrate metabolism.
Before starting treatment with Glurenorm, discuss it with your doctor, pharmacist, or nurse:
Treatment of diabetes requires regular medical care. Remember to have regular check-ups with your doctor, especially when changing the dose of the medicine or changing to Glurenorm (see: "Driving and using machines").
Tell your doctor or pharmacist about all the medicines you are taking, or have recently taken, and about the medicines you plan to take.
Many medicines have a proven effect on glucose metabolism. Therefore, the doctor should be aware of the medicines you are taking - otherwise, it will not be possible to take into account potential interactions between medicines.
Concomitant use of the following medicines may enhance the effect of Glurenorm:
ACE inhibitors (used to treat hypertension), allopurinol (used to treat high uric acid levels in the blood, including gout), painkillers and non-steroidal anti-inflammatory medicines (used to treat rheumatic diseases and pain), antifungal medicines, chloramphenicol, clarithromycin, fluoroquinolones, sulfonamides, and tetracyclines (all antibiotics used to treat infections), clofibrate (used to treat high cholesterol levels), anticoagulant medicines (coumarin derivatives), heparin, and sulfinpyrazone (blood thinners), MAO inhibitors, and tricyclic antidepressants (used to treat depression), cyclophosphamide and its derivatives (used to treat cancer), insulin, and other blood sugar-lowering medicines.
The following medicines used to treat hypertension may potentially enhance the blood sugar-lowering effect and mask the symptoms of hypoglycemia: beta-adrenergic receptor blockers, clonidine, reserpine, and guanethidine.
Concomitant use of the following medicines may weaken the blood sugar-lowering effect of Glurenorm: aminoglutethimide (used to treat cancer), corticosteroids (used to treat inflammatory conditions), diazoxide, thiazide diuretics, and loop diuretics (used to treat hypertension), oral contraceptives (to prevent pregnancy), sympathomimetics (such as bronchodilators used to treat asthma), rifampicin and rifabutin (used to treat tuberculosis), thyroid hormones, glucagon (a pancreatic hormone), phenothiazines (used to treat mental illnesses), nicotinic acid (used as a dietary supplement and to treat high cholesterol and other fat levels), barbiturates (used as sedatives), and phenytoin (used to treat epilepsy).
Enhanced or reduced effect of Glurenorm, lowering blood sugar levels, has been reported after the use of H receptor antagonists (e.g., cimetidine, ranitidine - to reduce stomach acid secretion) and alcohol.
Glurenorm should be taken with strict adherence to the diet, as recommended by the doctor. After taking Glurenorm, never skip or delay a meal, as this may significantly lower blood sugar levels and potentially lead to loss of consciousness (e.g., when taking the tablet before a meal instead of at the start of the meal).
Adhere to the diet, as in the case of diabetes, the diet is mainly aimed at controlling the patient's body weight and is independent of the treatment prescribed by the doctor.
Alcohol may enhance or weaken the blood glucose-lowering effect of Glurenorm.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
The doctor will advise stopping Glurenorm and changing the treatment to insulin.
In pregnant women, particularly careful and intensive control of blood glucose levels is necessary. When taking oral blood sugar-lowering medicines, this is not possible.
Therefore, Glurenorm should not be used during pregnancy and breastfeeding.
No studies have been conducted on the effect on the ability to drive and use machines. If drowsiness, dizziness, and vision disturbances or other clinical symptoms of hypoglycemia occur while taking Glurenorm, it is essential to avoid performing potentially hazardous activities, such as driving and using machines.
If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking this medicine.
This medicine should always be taken exactly as advised by the doctor. In case of doubt, consult the doctor or pharmacist.
The tablet can be divided into equal doses.
Initial treatment
Treatment with Glurenorm usually starts with half a tablet (15 mg) during breakfast. Glurenorm should be taken at the start of a meal. After taking Glurenorm, never skip a meal.
If treatment with half a tablet during breakfast is insufficient, the doctor will gradually increase the dose. If the prescribed dose is not more than two tablets (60 mg), the daily dose of Glurenorm can be taken once a day during breakfast. If higher daily doses are necessary, better control can be achieved by taking the medicine in two or three divided doses throughout the day. In this case, the largest dose should be taken during breakfast.
The maximum recommended daily dose is 4 tablets (120 mg).
Glurenorm should not be used in children and adolescents due to the lack of data on its safety and efficacy.
In case of overdose, consult a doctor or pharmacist.
Overdose of Glurenorm may cause low blood sugar levels - also prolonged - with symptoms such as loss of consciousness, rapid heartbeat, sweaty skin, anxiety, hyperactive reflexes (e.g., tremors), or gastrointestinal disorders.
In case of a missed dose, take the missed dose as soon as possible, but do not take a double dose to make up for the missed dose. Remember to take Glurenorm tablets only at the start of a meal. Take the next dose at the usual time.
Before stopping Glurenorm, consult a doctor.
In case of any further doubts about the use of this medicine, consult a doctor or pharmacist.
Like all medicines, Glurenorm can cause side effects, although not everybody gets them.
The following frequency classification has been used:
very common: more than 1 in 10 patients;
common: more than 1 in 100 patients, but less than 1 in 10 patients;
uncommon: more than 1 in 1000 patients, but less than 1 in 100 patients;
rare: more than 1 in 10,000 patients, but less than 1 in 1000 patients;
very rare: less than 1 in 10,000 patients
Blood and lymphatic system disorders
Rare:
reduced white blood cell count (agranulocytosis), reduced white blood cell count (leukopenia), reduced platelet count (thrombocytopenia)
Metabolism and nutrition disorders
Common:
Rare:
low blood sugar levels
decreased appetite
Nervous system disorders
Uncommon:
Rare:
drowsiness, dizziness, headache
tingling sensation
Eye disorders
Uncommon:
vision disturbances
Cardiac disorders
Rare:
angina pectoris, arrhythmias (heart rhythm disorders)
Vascular disorders
Rare:
cardiovascular failure (heart and circulation disorders), low blood pressure
Gastrointestinal disorders
Uncommon:
diarrhea, vomiting, abdominal discomfort, nausea, constipation, dryness of the mucous membranes in the mouth
Hepatobiliary disorders
Rare:
reduced bile flow
Skin and subcutaneous tissue disorders
Uncommon:
Rare:
rash, itching
Stevens-Johnson syndrome (a severe skin disease in which the top layer of the skin dies and peels off), photosensitivity, urticaria
General disorders and administration site conditions
Rare:
chest pain, feeling of tiredness
If you experience any side effects, including any side effects not listed in the leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Store in a room temperature (15-25°C).
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Blister packs in a cardboard box.
Each pack contains 50 tablets.
For more detailed information, consult the marketing authorization holder or parallel importer.
Menarini Benelux N.V./S.A.
De Kleetlaan 3
1831 Machelen
Belgium
Qualiphar N.V.
Rijksweg 9
B-2880 Bornem
Belgium
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Laboratorium Galenowe Olsztyn Sp. z o.o.
ul. Spółdzielcza 25A
11-001 Dywity
CEFEA Sp. z o.o. Sp. komandytowa
ul. Działkowa 56
02-234 Warszawa
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warszawa
IVA Pharm Sp. z o.o.
ul. Drawska 14/1
02-202 Warszawa
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Marketing authorization number in Belgium, the country of export: BE111851
Parallel import authorization number: 244/18
[Information about the trademark]
---------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
Overdose of sulfonylurea medicines may cause hypoglycemia.
Symptoms
Possible occurrence of a hypoglycemic reaction (also prolonged), such as loss of consciousness, tachycardia, sweaty skin, anxiety, hyperactive reflexes, and gastrointestinal disorders.
Treatment
Immediate oral or intravenous administration of glucose. Control of blood glucose levels and further administration of glucose may be necessary.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.